Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era. (scientific article published on 27 July 2011)

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Q27860904

Weekly epirubicin versus doxorubicin as second line therapy in advanced breast cancer. A randomized clinical trial

Q28334642

Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base

Q31070408

Metaplastic carcinoma of the breast clinical presentation, treatment results and prognostic factors

Q36425158

Metaplastic carcinoma of the breast, an unusual disease with worse prognosis: the experience of the European Institute of Oncology and review of the literature

Q36606990

Epirubicin is not Superior to Doxorubicin in the Treatment of Advanced Soft Tissue Sarcomas.The Experience of the EORTC Soft Tissue and Bone Sarcoma Group

Q36690873

International guidelines for management of metastatic breast cancer: combination vs sequential single-agent chemotherapy

Q37329165

Overall survival and post-progression survival in advanced breast cancer: a review of recent randomized clinical trials

Q37701152

Comparison of CHOP-B vs CEOP-B in 'poor prognosis' non-Hodgkin's lymphomas. A randomized trial.

Q42490396

Biphasic metaplastic sarcomatoid carcinoma of the breast

Q42680108

Successful treatment of biphasic metaplastic sarcomatoid carcinoma of the breast by evaluation of immunohistochemical markers

Q43027264

Responses to liposomal Doxorubicin, bevacizumab, and temsirolimus in metaplastic carcinoma of the breast: biologic rationale and implications for stem-cell research in breast cancer.

Q54597304

P433

issue

P407

language of work or name

English

Q1860

P921

main subject

chemotherapy

Q974135

Metaplastic carcinoma

Q6823150

P304

page(s)

345-351

P577

publication date

2011-07-27

P1433

published in

Breast Cancer Research and Treatment

Q326085

P1476

title

Lack of efficacy to systemic chemotherapy for treatment of metaplastic carcinoma of the breast in the modern era

P478

volume

130

Reverse relations

cites work (P2860)

Q64923684	Carcinosarcoma of the breast: A case of breast conservation surgery and breast reconstruction.
Q64101482	Clinical outcomes and patterns of care in the treatment of carcinosarcoma of the breast
Q41144888	Clinicopathological characteristics and prognosis of metaplastic carcinoma of the breast
Q89842731	Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers
Q38830663	Comprehensive profiling of metaplastic breast carcinomas reveals frequent overexpression of programmed death-ligand 1.
Q92433951	Granulocyte-colony-stimulating factor-producing metaplastic carcinoma of the breast with significant elevation of serum interleukin-17 and vascular endothelial growth factor levels
Q48219599	Human Metaplastic Breast Carcinoma and Decorin
Q50075112	Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer
Q37624202	Metaplastic Breast Carcinoma Versus Triple-Negative Breast Cancer: Survival and Response to Treatment
Q35121897	Metaplastic breast cancer: a comparison between the most common histologies with poor immunohistochemistry factors
Q30447049	Metaplastic breast cancer: histologic characteristics, prognostic factors and systemic treatment strategies
Q92645987	Metaplastic breast carcinoma: a clinical analysis of 26 cases
Q33799213	Metaplastic breast carcinomas - analysis of prognostic factors in a case series
Q37685312	Mixed epithelial and mesenchymal metaplastic carcinoma (carcinosarcoma) of the breast: a case report
Q38078338	Molecular alterations in metaplastic breast carcinoma
Q89666620	Outcomes after Treatment of Metaplastic Versus Other Breast Cancer Subtypes
Q33873330	Pathological features of triple-negative breast cancers that showed progressive disease during neoadjuvant chemotherapy
Q93128639	Pathway activity profiling of growth factor receptor network and stemness pathways differentiates metaplastic breast cancer histological subtypes
Q38687963	Predictive factors on outcomes in metaplastic breast cancer.
Q91708440	Quantitative proteomic landscape of metaplastic breast carcinoma pathological subtypes and their relationship to triple-negative tumors
Q34005143	Rare breast cancer subtypes: histological, molecular, and clinical peculiarities
Q49795418	Rare variant of metaplastic carcinoma of the breast: a case report and review of the literature
Q104486602	The longitudinal risk of mortality between invasive ductal carcinoma and metaplastic breast carcinoma

P356	DOI	10.1007/S10549-011-1686-9
P698	PubMed publication ID	21792625